#United States #New York #Eli Lilly #Ro #Foundayo™

Ro Introduces Foundayo™

In an exciting development for the healthcare sector, Ro has announced the inclusion of Foundayo™ (orforglipron), Eli Lilly's latest innovation in GLP-1 medication, into its service offerings. This marks a significant addition to Ro’s comprehensive formulary of FDA-approved GLP-1 medications, providing patients with improved options in managing obesity and overweight conditions coupled with weight-related health issues.

What is Foundayo™?

Foundayo™ is lauded as a once-daily oral treatment catered toward adults who are dealing with obesity or overweight challenges. By offering this latest GLP-1 therapy, Ro aims to enhance patient access to effective treatment options and simplify the weight-loss journey for many. Ro has emerged as a dominant force in direct-to-patient healthcare, spearheading innovation by providing accessible medications directly via telehealth services.

Comprehensive Accessibility

The beauty of Ro's platform lies in its ability to connect eligible patients with licensed providers who can help identify the most suitable GLP-1 treatment based on factors such as insurance coverage, cost, and individual clinical needs. Whether a patient is beginning their weight loss journey or seeking to maintain their progress, Ro aims to deliver an affordable and flexible treatment solution. The starting cash pay price for Foundayo™ is set at $149 per month for the lowest dose, with additional membership fees applicable.

Zach Reitano, the co-founder and CEO of Ro, expressed enthusiasm regarding the collaboration with Eli Lilly, emphasizing the significance of providing an economical treatment option that caters to diverse patient goals. He stated, “There is no one size fits all treatment for weight management, and Foundayo™ offers patients an affordable and flexible option to meet their goals.” This sentiment reflects Ro’s commitment to supporting individual patient journeys effectively.

Addressing Stigma and Access Issues

Despite the availability of GLP-1 medications for several years, many potential patients still refrain from pursuing treatment due to stigma, limited access, or concerns about how these medications might fit into their daily lives. Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly, echoed this concern and emphasized their dedication to expanding treatment access. By utilizing channels that reach patients where they are, they aim to assist individuals in achieving their weight loss targets.

A Leader in Obesity Care

Ro boasts one of the most extensive obesity care formularies among telehealth providers. With cash pay and insurance-eligible options, patients can enjoy the convenience of medications delivered directly to their homes or available for pick-up at retail pharmacies. The Ro GLP-1 Insurance Checker also facilitates a smooth process for verifying benefits coverage at no charge, leading patients to attain their required medications at the most competitive prices.

Having successfully assisted over 2 million individuals in comprehending their benefits coverage, Ro reaffirms its commitment to patient accessibility and education.

Conclusion

Ro's launch of Foundayo™ stands as a considerable advancement in the realm of weight management therapies. It not only showcases innovation in pharmaceutical technology but also underscores a robust movement toward accessible healthcare solutions, directly addressing the diverse needs of patients across the nation. For more details on membership and the full suite of GLP-1 options available through Ro, visit Ro's website.

• ---

This initiative by Ro paves the way for enhanced patient empowerment and a brighter future for those facing obesity-related challenges. With substantial resources and a commitment to individual needs, Ro is determined to create a lasting impact on the healthcare landscape.